Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: S.Vincent Rajkumar Clear advanced filters

  • S. Vincent Rajkumar says there is enough evidence to begin testing, and treating, people at high risk of the disease much earlier.

    • S. Vincent Rajkumar
    Comments & Opinion
    Nature
    Volume: 587, P: S63

  • Data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility.

    • Prashant Kapoor
    • S. Vincent Rajkumar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 14, P: 73-74

  • The numerous active agents and possible drug combinations for the treatment of multiple myeloma present challenges in terms of the best regimens for first-line therapy, role of transplantation, and maintenance therapy. Should treatment approaches achieve cure or disease control? This Review provides an update on the treatment of multiple myeloma, with a focus on recent advances and newly diagnosed disease.

    • S. Vincent Rajkumar
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 479-491

  • The current definition of multiple myeloma is outdated. The diagnosis requires evidence of overt end-organ damage, preventing initiation of early therapy when the malignancy is at its most susceptible stage. We propose an evidence-based approach using more-sensitive and highly specific biomarkers to update the definition of this disease.

    • S. Vincent Rajkumar
    • Giampaolo Merlini
    • Jesus F. San Miguel
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 9, P: 494-496

  • A minority of patients with primary central nervous system lymphoma (PCNSL) achieve a complete response to therapy and most patients have a poor prognosis. A recent randomized phase II trial demonstrated that the addition of high-dose cytarabine to high-dose methotrexate increases the complete response rate and improves patient outcome.

    • Stephen M. Ansell
    • S. Vincent Rajkumar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 7, P: 125-126

  • In a recent randomized trial, lenalidomide plus low-dose dexamethasone prolonged overall survival in patients with high-risk smoldering multiple myeloma. Although the results are impressive, the generalizability is limited to a small subset of patients. Additional studies are needed to identify specific patient populations who can benefit from early intervention.

    • S. Vincent Rajkumar
    • Robert A. Kyle
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 10, P: 554-555

  • It has been a decade of remarkable progress in the field of haematological malignancies with the rapid translation of basic science discoveries into effective targeted therapies. We discuss the most exciting advances in this field, many of which have already produced meaningful improvements in survival and quality of life of patients.

    • S. Vincent Rajkumar
    • Philippe Moreau
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 11, P: 628-630

  • Of three randomized trials testing lenalidomide maintenance in myeloma, a survival benefit is apparent in one. An increased risk of second cancers is seen in all three trials. Maintenance must be considered after a review of risks and benefits, but it is premature to recommend lenalidomide maintenance for all patients.

    • S. Vincent Rajkumar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 9, P: 372-374

  • Multiple myeloma, a malignancy of plasma cells, remains incurable and is poorly understood. Using next-generation sequencing of several multiple myeloma genomes reveals that this disease involves mutations of genes involved in protein translation, histone methylation and blood coagulation. The study suggests that BRAF inhibitors should be evaluated in multiple myeloma clinical trials.

    • Michael A. Chapman
    • Michael S. Lawrence
    • Todd R. Golub
    ResearchOpen Access
    Nature
    Volume: 471, P: 467-472